We used in silico methods to screen a library of 1,013 compounds for possible binding to the allosteric site in farnesyl diphosphate synthase (FPPS). Two of the 50 predicted hits had activity against either human FPPS (HsFPPS) or Trypanosoma brucei FPPS (TbFPPS), the most active being the quinone methide celastrol (IC 50 versus TbFPPS ∼20 μM). Two rounds of similarity searching and activity testing then resulted in three leads that were active against HsFPPS with IC 50 values in the range of ∼1-3 μM (as compared with ∼0.5 μM for the bisphosphonate inhibitor, zoledronate). The three leads were the quinone methides taxodone and taxodione and the quinone arenarone, compounds with known antibacterial and/or antitumor activity. We then obtained X-ray crystal structures of HsFPPS with taxodione+zoledronate, arenarone+zoledronate, and taxodione alone. In the zoledronate-containing structures, taxodione and arenarone bound solely to the homoallylic (isopentenyl diphosphate, IPP) site, not to the allosteric site, whereas zoledronate bound via Mg 2+ to the same site as seen in other bisphosphonate-containing structures. In the taxodione-alone structure, one taxodione bound to the same site as seen in the taxodione+zoledronate structure, but the second located to a more surface-exposed site. In differential scanning calorimetry experiments, taxodione and arenarone broadened the native-to-unfolded thermal transition (T m ), quite different to the large increases in ΔT m seen with biphosphonate inhibitors. The results identify new classes of FPPS inhibitors, diterpenoids and sesquiterpenoids, that bind to the IPP site and may be of interest as anticancer and antiinfective drug leads.
F
arnesyl diphosphate synthase (FPPS) catalyzes the condensation of isopentenyl diphosphate (IPP; compound 1 in Fig. 1 ) with dimethylallyl diphosphate (DMAPP; compound 2 in Fig. 1 ) to form the C 10 isoprenoid geranyl diphosphate (GPP; compound 3 in Fig. 1 ), which then condenses with a second IPP to form the C 15 isoprenoid, farnesyl diphosphate (FPP; compound 4 in Fig. 1 ). FPP then is used in a wide range of reactions including the formation of geranylgeranyl diphosphate (GGPP) (1) , squalene (involved in cholesterol and ergosterol biosynthesis), dehydrosqualene (used in formation of the Staphylococcus aureus virulence factor staphyloxanthin) (2) , undecaprenyl diphosphate (used in bacterial cell wall biosynthesis), and quinone and in heme a/o biosynthesis. FPP and GGPP also are used in protein (e.g., Ras, Rho, Rac) prenylation, and FPPS is an important target for the bisphosphonate class of drugs (used to treat bone resorption diseases) such as zoledronate (compound 5 in Fig. 1 ) (3) . Bisphosphonates targeting FPPS have activity as antiparasitics (4) , act as immunomodulators (activating γδ T cells containing the Vγ2Vδ2 T-cell receptor) (5) , and switch macrophages from an M2 (tumorpromoting) to an M1 (tumor-killing) phenotype (6) . They also kill tumor cells (7) and inhibit angiogenesis (8) . However, the bisphosphonates in clinical use (zoledronate, alendronate, risedronate, ibandronate, etidronate, and clodronate) are very hydrophilic and bind avidly to bone mineral (9) . Therefore, there is interest in developing less hydrophilic species (10) that might have better activity against tumors in soft tissues and better antibacterial (11) and antiparasitic activity.
The structure of FPPS (from chickens) was first reported by Tarshis et al. (12) and revealed a highly α-helical fold. The structures of bacterial and Homo sapiens FPPS (HsFPPS) are very similar; HsFPPS structure (13, 14) is shown in Fig. 2A . There are two substrate-binding sites, called here "S1" and "S2." S1 is the allylic (DMAPP, GPP) binding site to which bisphosphonates such as zoledronate bind via a [Mg 2+ ] 3 cluster (15) ( Fig. 1 ) showing zoledronate in S1 and Nov_980 (compound 6) in the A site is shown in a stereo close-up view in Fig. 2B , superimposed on a zoledronate+IPP structure (PDB ID code 2F8Z) in S2. Whether the allosteric site serves a biological function (e.g., in feedback regulation) has not been reported. Nevertheless, highly potent inhibitors (IC 50 ∼80 nM) have been developed (10) , and the best of these newly developed inhibitors are far more hydrophobic than are typical bisphosphonates
Significance
There is an ever-present need for new drugs because of drug resistance. An enzyme called "farnesyl diphosphate synthase" (FPPS) is one important drug target, and drugs called "bisphosphonates" that inhibit this enzyme are of interest both as cancer therapeutics and as antibacterial and antiparasitic drug leads. However, they bind avidly to bone and so are ineffective against most tumors and most infectious organisms. Here, we report the discovery of compounds that lack a bone-binding feature that target FPPS in a unique way, as observed at the atomic level. They also can bind to other protein targets, providing a potentially important approach, multitarget inhibition, that is expected to increase efficacy and decrease the likelihood that resistance will develop.
(∼2.4-3.3 for cLogP vs. ∼−3.3 for zoledronate) and are expected to have better direct antitumor effects in soft tissues (10) .
In our group we also have developed more lipophilic compounds (e.g., compound 7 in Fig. 1 ) (17, 18) as antiparasitic (19) and anticancer drug leads (18) and, using computational methods, have discovered other novel nonbisphosphonate FPPS inhibitors (e.g., compound 8 in Fig. 1 ) that have micromolar activity against FPPS (20) . In this study, we extended our computational work and tried to discover other FPPS inhibitors that target the A site. Such compounds would be of interest because they might potentiate the effects of zoledronate and other bisphosphonates, as reported for other FPPS inhibitors (21) , and have better tissue distribution properties in general.
Results
Discovery of FPPS Inhibitors. We sought to find FPPS inhibitors by using virtual screening with both X-ray structures and structures obtained from molecular dynamics (MD) simulations. We first carried out an MD simulation of HsFPPS based on the crystal structure of the allosteric site inhibitor Nov_823 (PDB ID code 3N6K), with and without the inhibitor. Full details are given in Methods and Materials. The structural ensemble chosen for the virtual screening was representative of both snapshots from the MD simulation and the allosteric site FPPS crystal structures that previously were demonstrated to be valuable in virtual screening (20) : PDB ID codes 3N1V, 3N1W, 3N3L, 3N5H, 3N5J, 3N6K, 3N45, 3N46, and 3N49. Structures representing the conformational variability of the allosteric site during the simulations were extracted using clustering in which frames taken every 10 ps were extracted from the MD trajectories. These frames were aligned using all C α atoms that were within 10 Å of the ligand in the ligand-bound starting structure. Subsequent clustering was performed by rmsd using conformational clustering (22) resulting in five apo and four ligand-bound clusters that represented at least 90% of the trajectories. The total structural ensemble for the virtual screens thus consisted of 18 FPPS structures: nine from the MD simulations, and nine X-ray structures.
Virtual screening was performed using the National Cancer Institute (NCI) diversity set III, a subset of the full NCI compound database. Ligands were prepared using LigPrep (23), adding missing hydrogen atoms and generating all possible ionization states as well as tautomers. The final set used for virtual screening contained 1,013 compounds. Docking simulations were performed with both AutoDock Vina (24) and Glide (25) (26) (27) . The individual AutoDock Vina and Glide rankings were combined to form a consensus list of compounds that scored well with both methods. The seven top-scoring compounds from AutoDock Vina and Glide, respectively, and the top 36 compounds from the consensus list were chosen as the final 50 compounds for experimental investigation (SI Appendix, Fig. S1 ).
We obtained these 50 compounds from the Drug Synthesis and Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute (NCI/DTP) and tested them for inhibition of HsFPPS and TbFPPS, the latter being of interest because it is an antiparasitic drug target (28) . In an initial screen we tested compounds for FPPS inhibition (29) at an inhibitor concentration of 25 μM. Compounds that showed any inhibition then were retested, . Zoledronate binds to the allylic site S1, IPP binds to the homoallylic site S2, and the allosteric site inhibitor binds to the A site. Active-site "DDXXD" residues are indicated, as are Mg 2+ molecules (green and yellow spheres, respectively). The views are in stereo.
and a full dose-response curve was obtained. There were two hits: celastrol (compound 9 in Fig. 1 ) and NSC9037, 2,6,7-trihydroxy-9-(2-hydroxyphenyl)xanthen-3-one (compound 10 in Fig. 1 ). These compounds had the following IC 50 values in FPPS inhibition: compound 9:, TbFPPS, 17 μM and HsFPPS, no activity; compound 10: TbFPPS, 54 μM; HsFPPS, 81 μM (SI Appendix, Table  S1 ). Both compounds are quinone methides, and compound 9 has diverse biological activities (30) (31) (32) (33) . Therefore we elected to use compound 9 as the basis for a similarity search using the NCI/ DTP option in PubChem (https://pubchem.ncbi.nlm.nih.gov/) with compounds again being obtained from the NCI/DTP (http://dtp. cancer.gov). Twenty-five compounds (SI Appendix, Fig. S2 ) were tested against both HsFPPS and TbFPPS. The only compound with activity was NSC122419, the quinone methide taxodione (compound 11 in Fig. 1 ), which had an IC 50 of 1.2 μM against HsFPPS (SI Appendix, Table S1 ); in comparison, zoledronate had an IC 50 of 0.5 μM under the same assay conditions.
We then carried out a second similarity search based on taxodione (compound 11) and tested 15 compounds (SI Appendix, Fig. S3 ) from the NCI/DTP against HsFPPS. There were two hits with IC 50 in the 1-3 μM range: the quinone methide taxodone (compound 12 in Fig. 1 ) and the quinone arenarone (compound 13 in Fig. 1 ), both of which have been reported to have antiinfective or anticancer activity (34) (35) (36) (37) (38) (39) . All three terpenoid inhibitors (compounds 11, 12, and 13) thus contain either the hydroxyquinone methide fragment found in the terpenoid celastrol (compound 9) and compound 10 or a quinone moiety (compound 13); all three compounds (11, 12, and 13) are quite active against FPPS (SI Appendix, Table S1 ) and have been reported to be active against tumor cells (35, 40, 41) . We also tested compounds 9, 11, and 13 against the MCF-7 tumor cell line and found IC 50 values for cell growth inhibition (SI Appendix, Table  S1 ) of 0.2, 2, and 17 μM, respectively. Compounds 11, 12, 13 are all slightly more hydrophobic than the A-site inhibitors (10) with cLogP ∼4 for taxodione and taxodone, and cLogP ∼5 for arenarone, vs. ∼3.3 for the most potent A-site inhibitor (10) . To see if there was any activity against geranylgeranyl diphosphate synthase (GGPPS), another potential drug target, we tested all hits against an expressed human GGPPS (HsGGPPS). There was much less activity than with FPPS (compound 9, 32 μM; compound 10, > 200 μM; compound 11, 20 μM; compound 12, 46 μM; compound 13, 21 μM; SI Appendix, Table S1 ).
X-Ray Crystallographic Investigations. We next sought to investigate how compounds 11, 12, and 13 bind to HsFPPS. We were unsuccessful in obtaining crystals containing compound 12 (taxodone), but we did obtain three other crystal structures: taxodione+ zoledronate (PDB ID code 4P0V); arenarone+zoledronate (PDB ID code 4P0W), and taxodione alone (PDB ID code 4P0X) in which there were two bound taxodione molecules. Crystals diffracted to 2.4 Å (compound 11+zoledronate), 2.4 Å (compound 13+zoledronate), and 2.5 Å (compound 11 alone). Full data acquisition and refinement details are given in Table 1 , and experimental details are given in Materials and Methods. Ligand electron densities are shown in SI Appendix, Taxodione (compound 11) crystallized together with one molecule of zoledronate (compound 5) and three Mg 2+ ; stereo views of the structure (PBD ID code 4P0V) are shown in Fig. 3 A and B. Zoledronate binds, as expected, to the S1 site via three Mg 2+ and there is a 0.3-Å rmsd between all zoledronate atoms and Mg 2+ in the taxodione+zoledronate+Mg 2+ structure vs. the zoledronate+IPP+Mg 2+ alone structure (PDB ID code 2F8Z). However, the taxodione ligand does not bind to the A site found with the Novartis inhibitor compound 6 (PDB ID code 3N46) (shown superimposed on the taxodione+zoledronate+Mg 2+ structure in Fig. 3C ). It is particularly interesting that the quinone methide fragment in this taxodione+zoledronate structure occupies the IPP diphosphate-binding site (Fig. 3D) . No other FPPS inhibitors (except for S-thiolo-IPP) bind to this S2 site.
As noted above, there are two ligand-binding sites in FPPS. The S1 site contains primarily the two DDXXD motifs involved in binding to the three Mg 2+ and the allylic substrate, DMAPP, with Mg 2+ facilitating diphosphate ionization. In Table 2 we show the results of a SCORECONS analysis (42) , which ranks residues in terms of their essential nature: A score of 1.000 means the residue is essential; a residue with a score of 0 is nonessential. The top 20 residues (minus structural G and P residues) are shown in Table 2 together with their ligand interactions. As can be seen in Table 2 , in addition to the catalytic Asps, numerous highly conserved Arg/Lys residues, including K57, R60, R112 and R113, K57, R60, and R113, are involved in electrostatic/hydrogen bond interactions with the IPP ligand in S2 (Fig. 4A) . Notably, R60 and R113 also are the ligands that are very close to the taxodione carbonyl and OH groups (Fig. 4B) ; a LigPlot (43) view of these interactions is shown in SI Appendix, Fig. S5 .
We next obtained the structure of taxodione (compound 11) alone bound to HsFPPS (PDB ID code 4P0X). Full data acquisition and structure refinement details are given in Table 1 , and experimental details are given in Materials and Methods. Electron densities are given in SI Appendix, Finally, we determined the structure of the arenarone+zoledr-onate+Mg 2+ complex (PDB ID code 4P0W). Full data acquisition and structure refinement details are given in Table 1 , and ex- perimental details are given in Materials and Methods. Electron densities are shown in SI Appendix, Fig. S4C . Ligand-protein interactions are shown in SI Appendix, Fig. S7 . The structure (Fig. 6  A and B) is quite similar to that seen in the taxodione+zoledronate+ Mg 2+ complex, with arenarone again occupying the IPP site, S2 (Fig. 6C) , and Arg60 again being in close proximity to one ligand, carbonyl oxygen ( Fig. 4C and SI Appendix, Fig. S7 ). Superposition of the taxodione+zoledronate+Mg 2+ , arenarone+zoledronate+ Mg
2+
, and 6+zoledronate+Mg 2+ structures in Fig. 6D again shows that taxodione and arenarone do not bind to the allosteric site A; presumably, the initial hit (celastrol) was detected because the pocket used in the in silico screen extends into the IPP pocket.
A Principal Component Analysis of FPPS Structures. The results described above are of interest because they show an unusual FPPS inhibitor binding mode, so we next investigated how these protein structures compared with previously reported HsFPPS structures. We first used the POVME program (44) to measure pocket volumes (for apo and deliganded structures). The results in SI Appendix, Table S2 ). In each case the closed pocket structures contain one bisphosphonate.
We then used principal component analysis (PCA) to analyze all these HsFPPS structures. PCA mathematically converts a number of possibly correlated multivariables into sets of linearly uncorrelated variables through orthogonal transformation, thereby reducing the dimensionality, or the number of variables, of the dataset. The first PC describes the largest variance in the dataset, allowing the data to spread most along PC 1. Each successive PC describes the next largest variance orthogonal to the previous PCs. We used PCA because in other work [on undecaprenyl diphosphate synthase (UPPS)] we found we could separate UPPS structures into open, closed, and semiopen states based on a 2D method, that is, using two principal components (PCs), whereas a 1D volume-only-based method did not permit such clustering. We sought to go beyond the volume-only descriptions of the structures.
The 39 structures (the three reported here plus 36 others) formed only two clusters: the open conformations noted above that were centered around PC1 = −30 Å, PC2 = 0 Å and the closed conformations noted above that were centered around PC1 = 10 Å, PC2 = 0 Å (Fig. 7A ). All the structures in the open form shown in Fig. 7A (2F7M, 2N1V, 3N1W , 3N3L, 3N49, 3N5H, 3N5J, 3N6K, 1FPS, and 4P0X) are either apo, allosteric site inhibitor (alone), or taxodione-alone liganded structures, whereas all the closed structures (4GA3, 3RYE, 3S4J, 4DEM,  4H5D, 4H5E, 4H5C, 4JVJ, 4L2X, 2RAH, 2VF6, 1YQ7, 1YV5,  2OPN, 2OPM, 3B7L, 2F89, 2F8C, 2F8Z, 2F92, 2F94, 2F9K,  3N45, 3N46, 1ZW5 , 2QIS, 4P0V, and 4P0W) contain a bisphosphonate and Mg 2+ (in some cases in addition to another ligand, such as taxodione, IPP, or one of the allosteric site inhibitors plus zoledronate). The two types of cluster or structure apparently originate from bisphosphonate binding via Mg 2+ to the DDXXD motifs (Fig. 2B ) and, as proposed previously (10), arise from the movement of the C terminus starting around residue 230, which here correlates with a major change in PC1 (Fig. 7B) .
These results raise the question as to which states are sampled in the two MD simulations used in the virtual screening. Results for the apo-FPPS simulation projected onto PC space are shown in Fig. 7C , and results for the liganded form (Nov_823/PDB ID code 3N6K) are shown in Fig. 7D . Both simulations start in the open state. However, as shown in Fig. 7C , the apo form simulation samples, primarily, partially closed conformations with a PC1 ∼−8Å, whereas the ligand-bound simulation exhibits two distinct conformational distributions: an open conformation (PC1 ∼−25Å) and a partially closed conformation (PC1 ∼−3Å), indicating that the ligand prevents pocket closing and thus perhaps providing a basis for the designation "allosteric." In Fig. 8 we show differential scanning calorimetry (DSC) results for HsFPPS (+Mg 2+ ) alone or in the presence of zoledronate at a ligand:protein molar ratio of 10:1 (ΔT m ∼25°C), as well as in the presence of 1, 2, and 10 taxodione molecules per protein, arenarone at a ligand:protein molar ratio of 10:1, and taxodione+zoledronate at a ligand:protein molar ratio of 10:1. As can be seen in Fig. 8 , there is no increase in T m with either taxodione or arenarone. Rather, with taxodione the endotherm broadens at molar ratios of 1:1 and 2:1 and is not detectable at a taxodione:FPPS molar ratio of 10:1. Likewise, no endotherm is detected in the presence of arenarone at a ligand:FPPS molar ratio of 10:1. These results are consistent with the observation that, unlike the situation with bisphosphonate/Mg 2+ binding, the FPPS/taxodione structure more closely resembles the apo structure in terms of PC1 clustering and pocket volume and thus has an unfolding transition that is similar in terms of T m to that seen with the ligand-free protein. However, the observation that the transition is not visible at higher ligand concentrations was unexpected and perhaps suggests that multiple taxodione molecules may bind to the unfolded protein; this observation, although perhaps somewhat speculative, would be consistent with the presence of two ligand-bound populations in the zoledronate+ taxodione system (Fig. 8D) .
Structure of the Taxodione/N-Acetyl Cysteine Adduct. The first hit we obtained from the in silico screen was the quinone methide celastrol (compound 9). This compound, extracted from Thunder of God vines, is a component of traditional Chinese medicines and has been of interest in the context of the development of therapeutics to treat a wide range of diseases (30) (31) (32) 47) . Early work suggested inhibition of Hsp90•Cdc37 (48) , but more recently several other targets, including annexin II and β-tubulin, have been reported (49) . This quinone methide is reported to react with proteins via Michael addition (49, 50) of cysteine thiol groups to form the adduct compound 14 (Fig. 9) . Like celastrol (compound 9), taxodione is a quinone methide that reacts with protein cysteine thiol groups, as was noted as early as 1970 with phosphofructokinase (51) . In addition, as does celastrol, taxodione is reported to have diverse biological activities (35, 38, 52) . This chemical reactivity, if combined with FPPS inhibition, might lead to potent multitarget inhibitors, perhaps including more tumor-specific (e.g., ras-bearing) targets.
To investigate how thiols might bond to taxodione, we used NMR and mass spectrometry. The high-resolution mass spectrum of a 1:1 taxodione:N-acetyl cysteine mixture indicated the formation of a 1:1 adduct, SI Appendix, Fig. S8A . However, as shown in Fig. 9A , there are four possible taxodione sites at which cysteine thiols might bind, leading to compounds 15-18, and certainly there are many possible stereoisomers. Nucleophilic attack at C2, C4, or C6 in celastrol has been proposed to be possible (50) ; with taxodione, an additional binding site would be to the second carbonyl group (to form compound 18). A 1 H NMR spectrum of the product is shown in SI Appendix, Fig. S8B and indicates only a single aromatic proton (Fig. 9B shows the downfield region), consistent with formation of the Michael adduct compound 17. The gradient-selected COSY spectrum (SI Appendix, Fig. S8D ) confirms this structure. The NOESY spectrum (SI Appendix, Fig. S8C ) exhibits the NOE correlations shown in Fig. 9C and indicates regiospecific, stereoselective addition leading to the product shown in Fig. 9D [basically the behavior reported in ref. 50 with celastrol, which binds several nucleophiles at the same site (48, 50) ].
However, the inhibition effects we see with HsFPPS are not the result of covalent enzyme modification. If we use 100-μM enzyme concentrations (100× that in the inhibition assays) as well as 100-μM inhibitor concentrations, we can see (via electrospray-ionization mass spectrometry; SI Appendix, Fig. S9 A and B) that approximately one in three FPPS has one bound taxodione, but this reaction would be ∼10,000 times slower in the enzyme inhibition assays in which the both enzyme and inhibitor concentrations are ∼1 μM. The same effect is seen with celastrol/ FPPS: About one in two FPPS is modified (SI Appendix, Fig.  S9C ), but here celastrol is not even an inhibitor of HsFPPS.
Conclusions
The results presented above are of interest for several reasons. First, we used in silico screening to discover inhibitors of farnesyl diphosphate synthase. Using MD-based methods followed by in silico and in vitro screening, we found that the triterpenoid celastrol, a quinone methide, inhibited Trypanosoma brucei FPPS (TbFPPS) with an IC 50 ∼20 μM. We then carried out two rounds of similarity searching leading to three leads having IC 50 values in the 1-3 μM range against human FPPS (as compared with 0.5 μM for zoledronate, under the same assay conditions). All three compounds were terpenoids: taxodone, taxodione, and arenarone. We then determined the structures of taxodione and arenarone bound to human FPPS. The unexpected result was that both terpenoids bound to the homoallylic, IPP-binding site (S2) and not to the allosteric site A, as might have been expected. The basis for this binding to the IPP site is that there are interactions between the ligand oxygen molecules and the highly conserved Arg and Lys residues that normally bind to the IPP substrate's diphosphate group with the hydrophobic terpenoid fragment interacting with a more hydrophobic site. The observation that celastrol and taxodione are both quinone methides that bind to several proteins via Michael addition (to protein thiols) and have been of interest as anticancer and antiinfective drug leads suggests that in the future it may be possible to develop analogs that more potently inhibit FPPS to provide novel multitarget inhibitors, based in part on the structural results presented here.
Methods and Materials
Computational Aspects. MD simulations of FPPS and cluster analysis. Systems prepared for simulations were based on the crystal structure (PDB ID code 3N6K) with the highest-affinity FPPS allosteric site inhibitor, 1-(carboxymethyl)-1H-benzo[g]indole-2-carboxylic acid (10) . Two different systems were built: apo and ligand-bound. Tleap (53) was used to neutralize the systems by adding Na + counter ions and solvating using a TIP3P water box. The fully solvated apo system contained 63,913 atoms, whereas the fully solvated ligand-bound system contained 65,359 atoms. Simulations were performed on each system independently. Minimization using SANDER (53) was carried out in two stages: 1,000 steps of minimization of solvent and ions with the protein and ligand restrained using a force constant of 500 kcal −1 ·mol −1 ·Å 2 , followed by a 2,500-step minimization of the entire system. An initial 20-ps MD simulation with weak restraints (10 kcal −1 ·mol −1 ·Å 2 ) on the protein and ligand atoms then was used to heat the system to 300 K. Subsequently, 100-ns MD simulations were performed on both systems under constant temperature/constant pressure ensemble conditions at 300 K using AMBER (53) and the ff99SBildn force field (54, 55) . Periodic boundary conditions were used, along with a nonbonded interaction cutoff of 10 Å. Bonds involving hydrogen atoms were constrained using the SHAKE algorithm (56) with 2-fs time steps. Pocket-Volume Calculations. To quantify the degree of openness of the structures seen in the PCA, we calculated the volume of the central protein pocket (containing the Mg   2+ , IPP, and zoledronate-binding sites). POVME (44) was used for pocket-volume calculations. The crystal structure of HsFPPS in complex with zoledronate and isopentenyl diphosphate (PDB ID code 2F8Z) was used as the reference structure. The coordinates of the following atoms were used as centers for POVME inclusion spheres: all three Mg 2+ , PA, PB, O3A, C1, and C3 of IPP, and P9, P14, C8, C18, and N15 of zoledronate. All proteins were superimposed onto 2F8Z, and all nonprotein atoms were removed for the volume calculations. Points were generated in POVME with a grid spacing of 1 Å using inclusion spheres with a 5-Å radius around the atom positions. The volume was calculated using the contiguous option (with contiguous seed spheres with a 3-Å radius centered at the same coordinates as the inclusion spheres). PCA. The PCA was performed using the Bio3D package in R (57). The PC space was built up using 36 reported HsFPPS structures together with the three structures described here. The resulting 39 structures underwent iterative rounds of structural superposition to determine the invariant core of the protein, a region that exhibits the least structural variance among all the protein structures. This core consists of residues 21, 23-25, 45-54, 58-72, 77-106, 109-112, 115-120, 124-175, 177, 193-196, 198-201, 207-219, 225-226, 228 , and 231-233. Subsequently, the experimental structures were super- imposed onto this core, and a PCA was used (58, 59) . All the experimental structures projected into the space spanned by PC1 and PC2, along which there is the most variance. The first two PCs account for 93% of all of the variance observed, and PC1 alone accounts for 88.7% of the variance observed. The PC space generated from the experimental structures served as the basis for the projection of the MD trajectories.
Experimental Aspects. Expression and purification of HsFPPS, TbFPPS, and HsGGPPS. The expression and purification of TbFPPS, HsFPPS, and HsGGPPS followed the protocols reported previously (17, 60, 61) . Protein crystallization, data collection, and refinement. Crystallization of HsFPPS followed the protocol reported previously with minor modifications (62) . HsFPPS (23 mg/mL) was incubated with 5 mM MgCl 2 and 1 mM taxodione and 1 mM zoledronate or 1 mM taxodione and 1 mM GPP or 1 mM arenarone and 1 mM zoledronate. The mixtures were incubated on ice for 3 h, and any precipitates formed were removed by centrifugation (17,000 × g for 5 min). HsFPPS plus inhibitor solutions then were mixed in a 1:1 ratio with reservoir buffer [1.2 M phosphate buffer (pH 5.0), 25% glycerol]. Protein and ligands mixtures were incubated using the hanging-drop method at 20°C until hexagonal crystals appeared. Crystals then were mounted and frozen in liquid nitrogen. Diffraction data were collected at the Life Sciences Collaborative Team (LS-CAT) beam-line 21ID-F at the Argonne National Laboratory. Data were processed by using HKL3000 (63) and refined by using CCP4 (64) and Coot (65) . The LigPlots (43) and Ramachandran plots were generated by Ligplot+ (66) and PDBsum (67), respectively. Protein and ligand structures were drawn using PyMOL (68) . Enzyme inhibition. HsFPPS, TbFPPS, and HsGGPPS inhibition assays were carried out as described previously (17, 20, 62) . Compounds first were screened at 25 μM using a PPi release assay (69); then full dose-response curves were obtained for the actives, and IC 50 values were obtained using the Prism program (www.graphpad.com). The screening libraries were obtained from the Drug Synthesis and Chemistry Branch, DPT/NCI. The purity of key compounds is shown in SI Appendix, Fig. S10 . Inhibition of tumor-cell growth. MCF-7 cell growth inhibition assays followed the basic protocol described previously (70) with slight modifications. Cells were subcultured in DMEM plus 10% (vol/vol) FBS. Cells were grown at 37°C in a 5% (vol/vol) CO 2 atmosphere. Five thousand cells per well were inoculated with compounds in a total of 90 μL medium covered with a gaspermeable sealing membrane (catalog no. BEM-1; Diversified Biotech) and wrapped by Parafilm, to avoid evaporation. Plates then were incubated for 4 d at 37°C in 5% CO 2 . Cancer cell inhibition assays were carried out by using a 3-(4,5-dimethylthiazole-2-yl)-2,5-diphenyltetrazolium bromide (MTT) cell proliferation assay kit (30-1010K; ATCC). After incubation, 10 μL of MTT reagent was added to each well, and plates were incubated for 3 h at 37°C in a 5% CO 2 atmosphere. After incubation, 100 μL of detergent (SDS) was added to each well to stop the reaction. After overnight incubation at room temperature in the dark, cell densities were counted by using a UV-VIS spectrophotometer at 570 nm. Dose-response curves and corresponding IC 50 s were fitted by using program Prism (www.graphpad.com). DSC. DSC experiments were carried out using a Microcal VP-DSC instrument. The HsFPPS protein concentration was 30 μM in 25 mM Tris buffer (pH 7.5), 25 mM NaCl, and 5 mM MgCl 2 . Zoledronate was added from an aqueous stock solution; taxodione and arenarone were from 20-mM stock solutions in DMSO. DMSO [final percentage ∼1.5% (vol/vol)] had no effect on the thermal transition. The scans covered the range of 10°C to 90°C at a scan rate of 10°C/h for all systems. All transitions were irreversible. The DSC thermograms were processed by using Origin 7.1 software (www.sigmaplot.com). Buffer vs. buffer scans were used for baseline correction. Electrospray-ionization mass spectrometry. Spectra of 100 μM HsFPPS in the absence or presence of 100 μM taxodione (compound 11) or celastrol (compound 9) were obtained by using a Waters Quattro Ultima electrospray ionization mass spectrometry system (Waters Corp.). Samples were incubated in 10 mM Tris (pH 7.4), 25 mM NaCl, 100 μM inhibitor, 0.5% DMSO, for 15 min at 23°C. Fig. S3. Structures of the 15 compounds based on a similarity search (on 11) , tested against HsFPPS. NSC122420 (12) is taxodone; NSC 613794 is arenarone (13) . 
